NBI 34041

Drug Profile

NBI 34041

Alternative Names: SB 723620

Latest Information Update: 11 Dec 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neurocrine Biosciences
  • Developer GlaxoSmithKline
  • Class Acenaphthenes; Antidepressants; Antispasmodics; Anxiolytics; Irritable bowel syndrome therapies
  • Mechanism of Action Corticotropin-releasing-hormone-Inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Irritable bowel syndrome; Major depressive disorder

Most Recent Events

  • 11 Dec 2003 Discontinued - Phase-I for Anxiety disorders in United Kingdom (unspecified route)
  • 11 Dec 2003 Discontinued - Phase-I for Depression in United Kingdom (unspecified route)
  • 11 Dec 2003 Discontinued - Phase-I for Irritable bowel syndrome in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top